Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Be the first to review this product

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Summary

The antibacterial drug market...
You can choose to pay by purchase order during checkout

Availability: In stock

$4,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GBI Research.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Summary

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body's immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.

In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:
- How big is the antibiotic pipeline?
- How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
- Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
- Which molecular targets are most popular in the current pipeline?
- How many late-stage products are active against drug-resistant bacteria?
- What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
- Which of the leading companies are expected to have the highest share of the market by 2022?
- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
- Which companies rely heavily of revenues derived from antibacterial drugs?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the antibacterial drug market in the context of the overall pipeline and current market landscape. It also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include pneumonia, MRSA, sepsis and tuberculosis.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
- Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for antibacterial therapies.

Additional Information

Additional Information

Publisher name GBI Research.
Format PDF
Page count 177
Publication date 9 Jan 2017
Table of contents

View sample report

 

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Disease Cluster Introduction 10
2.2 Symptoms 11
2.2.1 Pneumonia 11
2.2.2 MRSA 11
2.2.3 Sepsis 11
2.2.4 Tuberculosis 11
2.3 Diagnosis 12
2.3.1 Pneumonia 12
2.3.2 MRSA 12
2.3.3 Sepsis 12
2.3.4 Tuberculosis 12
2.4 Etiology and Pathophysiology 13
2.4.1 Pneumonia 13
2.4.2 MRSA 14
2.4.3 Sepsis 15
2.4.4 Tuberculosis 15
2.5 Epidemiology 16
2.5.1 Pneumonia 16
2.5.2 MRSA 17
2.5.3 Sepsis 17
2.5.4 Tuberculosis 18
2.6 Comorbidities and Complications 18
2.6.1 Pneumonia 19
2.6.2 MRSA 19
2.6.3 Sepsis 19
2.6.4 Tuberculosis 19
2.7 Prognosis 19
2.7.1 Pneumonia 19
2.7.2 MRSA 20
2.7.3 Sepsis 20
2.7.4 Tuberculosis 20
2.8 Treatment 20
2.8.1 Beta-lactams 21
2.8.2 Protein Synthesis inhibitors 22
2.8.3 Vaccines 23
2.8.4 Other Classes of Antibacterial Therapy 23
3 Key Marketed Products 24
3.1 Overview 24
3.2 Cubicin (daptomycin) _ Merck & Co 25
3.3 Augmentin _ GlaxoSmithKline 27
3.4 Prevnar 13 _ Pfizer 29
3.5 Infanrix _ GlaxoSmithKline 30
3.6 Boostrix _ GlaxoSmithKline 32
3.7 Zerbaxa _ Merck and Co 33
3.8 Bexsero _ GlaxoSmithKline 35
3.9 Zyvox _ Pfizer 36
3.10 Conclusion 38
4 Pipeline Landscape Assessment 39
4.1 Overview 39
4.2 Pipeline Development Landscape 39
4.3 Mechanisms of Action in Pipeline 42
4.4 Clinical Trial Landscape 45
4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type 46
4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type 50
4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type 53
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type 57
4.5 Conclusion 61
4.6 Assessment of Key Pipeline Products 61
4.6.1 Solithera _ Cempra 61
4.6.2 Arikace _ Insmed 62
4.6.3 Cadazolid _ Actelion 63
4.6.4 Plazomicin (plazomicin sulfate) _ Achaogen 64
4.6.5 V114 _ Merck & Co. 65
4.6.6 Suvratoxumab (MEDI4893) _ MedImmune 66
4.6.7 Pf-06290510 (SA4Ag vaccine) _ Pfizer 67
4.6.8 PF-06425090 _ Pfizer 68
4.6.9 Conclusion 69
5 Multi-Scenario Market Forecast to 2022 70
5.1 Overall Market Size 70
5.2 Generic Penetration 73
5.3 Revenue Forecast by Mechanism of Action 75
5.3.1 Immune Response 75
5.3.2 Bacterial Cell Wall Disruptor/Inhibitor 76
5.3.3 Protein Synthesis Inhibitors 77
5.3.4 DNA Inhibitors 78
5.3.5 Multiple Mechanisms of Action 79
6 Company Analysis and Positioning 80
6.1 Revenue and Market Share Analysis by Company 81
6.1.1 Pfizer _ Will it Maintain its Position as Market Leader? 85
6.1.2 GlaxoSmithKline _ Will Revenues for Key Products Continue to Grow Over Forecast Period? 86
6.1.3 Merck & Co _ How Will Key Approvals and Patent Expiries Affect Revenue? 87
6.1.4 Allergan _ Revenues to Rise Rapidly Following Market Entry 88
6.1.5 Cempra _ Set to Enter the Market in 2017 89
6.1.6 Insmed _ Set to Enter the Market in 2018 90
6.1.7 Otsuka _ How Will the Approval of Deltyba Affect Otsuka's Market Share? 91
6.1.8 Roche _ Revenues to Continue to Decline Due to Lack of Pipeline Products 92
6.1.9 Bayer _ Steady Decline as All Products Off-Patent 93
6.1.10 AstraZeneca _ Set to Revitalize its Position within the Market 94
6.2 Company Landscape 95
6.3 Marketed and Pipeline Portfolio Analysis 96
7 Strategic Consolidations 99
7.1 Licensing Deals 99
7.1.1 Deals by Region, Value and Year 99
7.1.2 Deals by Indication 100
7.1.3 Deals by Stage of Development and Value 101
7.1.4 Deals by Molecule Type, Mechanism of Action and Value 103
7.1.5 Licensing Deals Valued Above $100m 104
7.2 Co-development Deals 105
7.2.1 Deals by Region, Value and Year 105
7.2.2 Deals by Indication 107
7.2.3 Deals by Stage of Development and Value 107
7.2.4 Deals by Molecule Type and Value 109
7.2.5 Co-development Deals Valued Above $100m 109
8 Appendix 111
8.1 References 111
8.2 Table of all Pipeline Products 115
8.3 Table of Epidemiology Forecast 171
8.4 Abbreviations 173
8.5 Methodology 175
8.5.1 Coverage 175
8.5.2 Secondary Research 175
8.5.3 Market Size and Revenue Forecasts 175
8.5.4 Pipeline Analysis 176
8.5.5 Competitive Landscape 176
8.6 Contact Us 177
8.7 Disclaimer 177

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.